Precision BioSciences, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $51.1 million for the six months ended June 30, 2026, compared to a loss of $44.1 million for the same period in 2025. The company did not generate any revenue in the second quarter of 2026, a stark decline from $18,000 in the same quarter of the previous year. For the first half of 2026, total revenue reached $10.8 million, primarily attributed to milestone payments from collaboration agreements, including a $6.8 million revenue recognition under the TG License Agreement.
Operating expenses for the first half of 2026 decreased to $39.1 million from $44.0 million in the prior year, driven by reduced general and administrative costs, which fell from $17.7 million to $13.6 million. Research and development expenses also saw a slight decline, totaling $25.5 million compared to $26.4 million in the previous year. The decrease in expenses was attributed to operational discipline and a strategic pause in the development of certain programs, allowing the company to focus on its lead candidates, PBGENE-HBV and PBGENE-DMD.
In terms of operational developments, Precision BioSciences continues to advance its clinical programs. The company is actively recruiting patients for its PBGENE-HBV trial, which aims to provide a potentially curative treatment for chronic hepatitis B. Recent data presented at the EASL Congress indicated promising results, with significant reductions in viral markers observed in treated patients. Additionally, the company is progressing with its PBGENE-DMD program, which targets Duchenne muscular dystrophy, and has initiated clinical trial activities at recognized centers of excellence.
The company’s financial position remains precarious, with an accumulated deficit of $579.3 million as of June 30, 2026. Precision BioSciences had cash, cash equivalents, and restricted cash totaling $112.4 million, which it believes will be sufficient to fund operations through 2028, assuming continued fiscal discipline and successful capital raising efforts. However, the company acknowledges the need for substantial additional funding to support ongoing research and development activities, and it may face challenges in securing financing under current market conditions.
Looking ahead, Precision BioSciences remains focused on advancing its clinical trials and achieving regulatory milestones. The company plans to provide further updates on its PBGENE-HBV and PBGENE-DMD programs by the end of 2026, while also exploring potential collaborations and partnerships to enhance its financial stability and operational capacity.
About PRECISION BIOSCIENCES INC
Precision BioSciences is a clinical-stage biotechnology company specializing in in vivo gene editing therapies using its proprietary ARCUS platform. The platform employs engineered nucleases derived from natural homing endonucleases to develop precise, safe, and durable genetic treatments. The company focuses on therapies for infectious and genetic diseases, leveraging its innovative technology to create targeted, potentially curative solutions across multiple tissue types and conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov